Companies Deciphera Pharmaceuticals
Deciphera Pharmaceuticals (DCPH): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Deciphera Pharmaceuticals no longer files a proxy statement; its last pay data is FY2023.
CEO vs. named peers58th pct.Of 32 peer CEOs
CEO pay, last three years
- $9,414,654FY2021
- $3,554,485FY2022
- $6,010,712FY2023
CEO total pay was $6,010,712 in fiscal 2023, up from $3,554,485 in fiscal 2022.
FY2023: salary $738,200 · bonus $0 · stock awards $1,935,000 · option awards $2,837,100
Executives and directors
Daniel Martin · CCODashyant Dhanak · EVPMatthew Sherman · EVPSteven Hoerter · CEOThomas Kelly · CFODaniel Flynn · ExecutiveDennis L. Walsh · Independent DirectorEdward J. Benz Jr., M.D · Independent DirectorFrank S. Friedman · Independent DirectorJames A. Bristol, Ph.D · Independent DirectorJohn R. Martin · Independent DirectorPatricia L. Allen · Independent DirectorRon Squarer · Chair of the BoardSusan L. Kelley, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Deciphera Pharmaceuticals in fiscal 2023?
As disclosed, Steven Hoerter (President and Chief Executive Officer) was the highest-paid executive at Deciphera Pharmaceuticals in fiscal 2023, with total compensation of $6,010,712.
How does Deciphera Pharmaceuticals's chief executive pay compare to its disclosed peer group?
As disclosed, Steven Hoerter's total compensation ranked at the 58th percentile of Deciphera Pharmaceuticals's disclosed peer group.
How did shareholders vote on Deciphera Pharmaceuticals's executive compensation?
As disclosed, 97.47% of shareholders supported Deciphera Pharmaceuticals's executive compensation in the latest say-on-pay vote.
How much does Deciphera Pharmaceuticals spend in total on board compensation for fiscal 2023?
As disclosed, Deciphera Pharmaceuticals reported total board compensation of $536,966 for fiscal 2023.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Hoerter | $738,200 | $0 | $1,935,000 | $2,837,100 | $487,212 | $0 | $13,200 | $6,010,712 |
| President and Chief Executive Officer | ||||||||
| Dashyant Dhanak | 195,455 | 0 | 1,890,878 | 673,874 | 297,000 | 0 | 6,000 | 3,063,207 |
| EVP, Chief Scientific Officer | ||||||||
| Matthew Sherman | 573,500 | 0 | 510,468 | 747,860 | 283,883 | 0 | 13,200 | 2,128,911 |
| EVP, Chief Medical Officer | ||||||||
| Thomas Kelly | 507,875 | 0 | 510,468 | 747,860 | 251,398 | 0 | 13,200 | 2,030,801 |
| EVP, Chief Financial Officer & Treasurer | ||||||||
| Daniel Flynn | 501,970 | 0 | 510,468 | 747,860 | 0 | 0 | 239,087 | 1,999,385 |
| Founder and Former EVP, Chief Scientific Officer | ||||||||
| Daniel Martin | 496,065 | 0 | 345,235 | 506,139 | 218,269 | 0 | 13,200 | 1,578,908 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Steven Hoerter | $6,010,712 | $3,554,485 | $9,414,654 | ↑ +2,456,227 |
| Dashyant Dhanak | 3,063,207 | — | — | — |
| Matthew Sherman | 2,128,911 | 1,491,982 | 3,462,594 | ↑ +636,929 |
| Thomas Kelly | 2,030,801 | 1,405,209 | 3,380,862 | ↑ +625,592 |
| Daniel Flynn | 1,999,385 | 1,385,537 | 3,382,347 | ↑ +613,848 |
| Daniel Martin | 1,578,908 | 1,128,992 | 2,665,893 | ↑ +449,916 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is guided by our overarching philosophy of paying for demonstrable performance, designed to attract, motivate, and retain top-performing executives, establish competitive compensation opportunities that reward performance, and align the interests of our executive team members with the interests of our stockholders to drive the creation of sustainable long-term value.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Dashyant Dhanak | OPTION | 2023-09-15 | — | — | 65,900 | — | $673,874 |
| Daniel C. Martin | PSU | 2023-02-15 | — | 16,727 | — | 11,151 | 345,235 |
| Thomas Kelly | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | 510,468 |
| Dashyant Dhanak | RSU | 2023-09-15 | — | — | 140,900 | — | 1,890,878 |
| Daniel Flynn | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Thomas Kelly | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Matthew Sherman | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | 510,468 |
| Steven Hoerter | OPTION | 2023-02-15 | — | — | 250,000 | — | 2,837,100 |
| Daniel C. Martin | OPTION | 2023-02-15 | — | — | 44,600 | — | 506,139 |
| Matthew Sherman | OPTION | 2023-02-15 | — | — | 65,900 | — | 747,860 |
| Daniel Flynn | PSU | 2023-02-15 | — | 24,732 | — | 16,488 | 510,468 |
| Steven Hoerter | PSU | 2023-02-15 | — | 187,500 | 187,500 | — | 1,935,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Dashyant Dhanak | $1,890,878 | $0 | $673,874 | 0.0% |
| Daniel C. Martin | 0 | 345,235 | 506,139 | 40.6% |
| Thomas Kelly | 0 | 510,468 | 747,860 | 40.6% |
| Daniel Flynn | 0 | 510,468 | 747,860 | 40.6% |
| Matthew Sherman | 0 | 510,468 | 747,860 | 40.6% |
| Steven Hoerter | 0 | 1,935,000 | 2,837,100 | 40.5% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Sherman | Option | 438 | 54.87 | — |
| Matthew Sherman | RSU | 440 | — | 7,097 |
| Thomas Kelly | Option | 1,758 | 54.87 | — |
| Daniel Flynn | Option | 1,758 | 54.87 | — |
| Martin | Option | 1,758 | 54.87 | — |
| Thomas Kelly | RSU | 1,760 | — | 28,389 |
| Daniel Flynn | RSU | 1,760 | — | 28,389 |
| Martin | RSU | 1,760 | — | 28,389 |
| Martin | RSU | 4,150 | — | 66,940 |
| Thomas Kelly | RSU | 5,550 | — | 89,522 |
| Matthew Sherman | RSU | 5,550 | — | 89,522 |
| Daniel Flynn | RSU | 5,550 | — | 89,522 |
| Martin | RSU | 5,575 | — | 89,925 |
| Steven Hoerter | Option | 7,500 | 54.87 | — |
| Thomas Kelly | RSU | 8,244 | — | 132,976 |
| Matthew Sherman | RSU | 8,244 | — | 132,976 |
| Daniel Flynn | RSU | 8,244 | — | 132,976 |
| Martin | RSU | 9,110 | — | 146,944 |
| Martin | Option | 10,879 | 47.79 | — |
| Martin | RSU | 11,151 | — | 179,866 |
| Thomas Kelly | RSU | 13,665 | — | 220,416 |
| Matthew Sherman | RSU | 13,665 | — | 220,416 |
| Daniel Flynn | RSU | 13,665 | — | 220,416 |
| Thomas Kelly | Option | 14,554 | 47.79 | — |
| Matthew Sherman | Option | 14,554 | 47.79 | — |
| Daniel Flynn | Option | 14,554 | 47.79 | — |
| Thomas Kelly | RSU | 16,488 | — | 265,951 |
| Matthew Sherman | RSU | 16,488 | — | 265,951 |
| Daniel Flynn | RSU | 16,488 | — | 265,951 |
| Martin | Option | 28,472 | 8.27 | — |
| Martin | Option | 35,308 | 15.48 | — |
| Thomas Kelly | Option | 42,708 | 8.27 | — |
| Matthew Sherman | Option | 42,708 | 8.27 | — |
| Daniel Flynn | Option | 42,708 | 8.27 | — |
| Thomas Kelly | Option | 52,171 | 15.48 | — |
| Matthew Sherman | Option | 52,171 | 15.48 | — |
| Daniel Flynn | Option | 52,171 | 15.48 | — |
| Steven Hoerter | Option | 61,250 | 47.79 | — |
| Steven Hoerter | RSU | 62,500 | — | 1,008,125 |
| Dashyant Dhanak | Option | 65,900 | 13.42 | — |
| Dashyant Dhanak | RSU | 140,900 | — | 2,272,717 |
| Steven Hoerter | Option | 197,917 | 15.48 | — |
| Steven Hoerter | Option | 216,146 | 8.27 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James A. Bristol, Ph.DIndependent · Compensation (Chair) · Nominating/Governance · Science and Technology | $86,174 | $0 | $328,593 | — | $0 | $414,767 |
| Ron SquarerIndependent · Board Chair · Audit | 74,702 | 0 | 328,593 | — | 0 | 403,295 |
| Patricia L. AllenIndependent · Audit (Chair) | 69,960 | 0 | 328,593 | — | 0 | 398,553 |
| Edward J. Benz Jr., M.DIndependent · Nominating/Governance (Chair) · Science and Technology | 67,500 | 0 | 328,593 | — | 0 | 396,093 |
| Susan L. Kelley, M.DIndependent · Compensation · Science and Technology (Chair) | 67,460 | 0 | 328,593 | — | 0 | 396,053 |
| John R. MartinIndependent · Audit | 60,000 | 0 | 328,593 | — | 0 | 388,593 |
| Dennis L. WalshIndependent · Compensation | 57,460 | 0 | 328,593 | — | 0 | 386,053 |
| Frank S. FriedmanIndependent · Nominating/Governance | 53,710 | 0 | 328,593 | — | 0 | 382,303 |
| Steven L. HoerterEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $536,966 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $536,966 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Deciphera Pharmaceuticals as a peer
Companies that benchmark against DCPH
10 companies name DCPH as a compensation peer
The list of companies that name DCPH as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2023
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
MCRB Seres TherapeuticsSNDX Syndax PharmaceuticalsYMAB Y-mAbs TherapeuticsEQRX EQRxRCUS Arcus BiosciencesMRTX Mirati TherapeuticsARVN ArvinasAGIO Agios PharmaceuticalsFOLD Amicus TherapeuticsBBIO BridgeBio Pharma EQRxKPTI Karyopharm TherapeuticsARVN ArvinasALLO Allogene TherapeuticsCOGT Cogent BiosciencesCHRS Coherus BioSciencesKPTI Karyopharm TherapeuticsMRSN Mersana TherapeuticsNGM NGM BiopharmaceuticalsREPL Replimune GroupSRRK Scholar Rock Holding CorporationSWTX SpringWorks TherapeuticsNGM NGM BiopharmaceuticalsAGIO Agios PharmaceuticalsYMAB Y-mAbs TherapeuticsMRSN Mersana TherapeuticsSRRK Scholar Rock Holding CorporationFOLD Amicus TherapeuticsSWTX SpringWorks TherapeuticsMCRB Seres TherapeuticsCHRS Coherus BioSciencesBBIO BridgeBio Pharma
Peer reciprocity
The companies Deciphera Pharmaceuticals names as compensation peers that name it back in their own disclosed peer groups.
Syndax Pharmaceuticals (SNDX)145Y-mAbs Therapeutics (YMAB)146Coherus BioSciences (CHRS)147SpringWorks Therapeutics (SWTX)148
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Scholar Rock Holding Corporation | 2025 | David Hallal | $637,500 | $22,518,500 | $7,624,988 | $452,293 | $33,300,927 |
| 2 | Cogent Biosciences | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 4 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 5 | Mirati Therapeutics | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 6 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 7 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 8 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 9 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 10 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 11 | Deciphera Pharmaceuticals | 2023 | Steven Hoerter | 738,200 | 1,935,000 | 2,837,100 | 487,212 | 6,010,712 |
| 12 | NGM Biopharmaceuticals | 2022 | David Woodhouse | 610,000 | 0 | 5,072,750 | 250,000 | 5,933,500 |
| 13 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 14 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 15 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 16 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 17 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 18 | Seres Therapeutics | 2025 | Eric Shaff | 408,333 | 0 | 1,338,870 | 0 | 1,775,549 |
| 19 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| — | EQRx | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Deciphera Pharmaceuticals | 110% | Option 50 · PSU 50 · RSU 25 | No | Pearl Meyer & Partners, LLC |
| Agios Pharmaceuticals | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Coherus BioSciences | not disclosed | Option 100 | not disclosed | Aon |
| EQRx | not disclosed | not disclosed | not disclosed | not disclosed |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Mirati Therapeutics | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| NGM Biopharmaceuticals | 75% | Option 100 | not disclosed | Aon |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Scholar Rock Holding Corporation | not disclosed | not disclosed | No | Pay Governance |
| Seres Therapeutics | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-21 | 64,932,371 | 1,688,178 | 23,547 | 97.47% | Passed |
| 2021 | 2021-06-23 | 43,546,830 | 10,721,690 | 127,007 | 80.24% | Passed |
| 2020 | 2020-06-10 | — | — | — | — | — |
| 2019 | 2019-06-11 | — | — | — | — | — |
| 2018 | 2018-05-16 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-06-21 | 97.47%a |
| 2021 | 2021-06-23 | 80.24%b |
| 2020 | 2020-06-10 | —c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “If you abstain from voting on this proposal, your shares will not be counted as "votes cast" with respect to this proposal, and the abstention will have no effect on this proposal.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Patricia L. Allen | Director | 2024-06-11 | D | 4,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 3,269 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 7,181 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 2024-06-11 | D | 69,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 2024-06-11 | D | 65,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 2024-06-11 | D | 184,088 | — | — | Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 38,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 44,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 54,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 62,971 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 31,330 | — | — | Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | D | 43,951 | — | — | Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 298,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 250,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 415,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 270,357 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 395,735 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 72,763 | — | — | Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | D | 286,075 | — | — | Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 69,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 65,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2024-06-11 | D | 4,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2024-06-11 | D | 3,269 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 82,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 82,265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 72,261 | — | — | Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | D | 72,029 | — | — | Common | Form 4 ↗ |
| Ron Squarer | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ron Squarer | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Matthew Sherman | EVP & Chief Medical Officer | 2024-06-11 | A | 34,157 | — | — | Common | Form 4 ↗ |
| Patricia L. Allen | Director | 2024-06-11 | D | 10,233 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Steven L. Hoerter | Director | 2024-06-11 | A | 286,075 | — | — | Common | Form 4 ↗ |
| Dashyant Dhanak | EVP & Chief Scientific Officer | 2024-06-11 | A | 25,913 | — | — | Common | Form 4 ↗ |
| Daniel C. Martin | Chief Commercial Officer | 2024-06-11 | A | 20,163 | — | — | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | A | 34,157 | — | — | Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | A | 20,163 | — | — | Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 4,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 3,269 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank S. Friedman | Director | 2024-06-11 | D | 10,000 | — | — | Common | Form 4 ↗ |
| Edward J. Benz JR | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Edward J. Benz JR | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Edward J. Benz JR | Director | 2024-06-11 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Edward J. Benz JR | Director | 2024-06-11 | D | 7,181 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Edward J. Benz JR | Director | 2024-06-11 | D | 35,233 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 67,494 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Arthur Bristol | Director | 2024-06-11 | D | 22,150 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 4,727 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 3,269 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 52,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis L. Walsh | Director | 2024-06-11 | D | 11,000 | — | — | Common | Form 4 ↗ |
| John Richard Martin | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Richard Martin | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Richard Martin | Director | 2024-06-11 | D | 12,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Richard Martin | Director | 2024-06-11 | D | 52,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan L. Kelley | Director | 2024-06-11 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan L. Kelley | Director | 2024-06-11 | D | 3,269 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan L. Kelley | Director | 2024-06-11 | D | 18,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan L. Kelley | Director | 2024-06-11 | D | 9,570 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Susan L. Kelley | Director | 2024-06-11 | D | 24,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 38,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 44,600 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 54,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 62,971 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 9,711 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 4,531 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 34,243 | — | — | Common | Form 4 ↗ |
| Jama Pitman | SVP, Chief Development Officer | 2024-06-11 | D | 53,951 | — | — | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 69,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 65,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 82,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 82,265 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 103,219 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 5,650 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 85,456 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 42,478 | — | — | Common | Form 4 ↗ |
| Thomas Kelly | Chief Financial Officer | 2024-06-11 | D | 72,029 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (148 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Steven Hoerter. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 6,010,712. View filing ↗
- Section 01, Dashyant Dhanak. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 3,063,207. View filing ↗
- Section 01, Matthew Sherman. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 2,128,911. View filing ↗
- Section 01, Thomas Kelly. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 2,030,801. View filing ↗
- Section 01, Daniel Flynn. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 1,999,385. View filing ↗
- Section 01, Daniel Martin. DEF 14A, filed 2024-04-25. Section “Executive Compensation”. As printed: 1,578,908. View filing ↗
- Section 03, Dashyant Dhanak OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel C. Martin PSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Kelly PSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Dashyant Dhanak RSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Flynn OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Thomas Kelly OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Sherman PSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Hoerter OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel C. Martin OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Matthew Sherman OPTION. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Flynn PSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Hoerter PSU. DEF 14A, filed 2024-04-25. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 08, James A. Bristol, Ph.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 414,767. View filing ↗
- Section 08, Ron Squarer. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 403,295. View filing ↗
- Section 08, Patricia L. Allen. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 398,553. View filing ↗
- Section 08, Edward J. Benz Jr., M.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 396,093. View filing ↗
- Section 08, Susan L. Kelley, M.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 396,053. View filing ↗
- Section 08, John R. Martin. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 388,593. View filing ↗
- Section 08, Dennis L. Walsh. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 386,053. View filing ↗
- Section 08, Frank S. Friedman. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 382,303. View filing ↗
- Section 08, Steven L. Hoerter. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dashyant Dhanak 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dashyant Dhanak 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dashyant Dhanak 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ron Squarer 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew Sherman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patricia L. Allen 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven L. Hoerter 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dashyant Dhanak 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel C. Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank S. Friedman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward J. Benz JR 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward J. Benz JR 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward J. Benz JR 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward J. Benz JR 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward J. Benz JR 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Arthur Bristol 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis L. Walsh 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Richard Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Richard Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Richard Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Richard Martin 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan L. Kelley 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan L. Kelley 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan L. Kelley 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan L. Kelley 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan L. Kelley 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jama Pitman 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas Kelly 2024-06-11. Form 4, filed 2024-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-22. Item 5.07 · say-on-pay result. As reported: 97.47% (votes for as printed: 64,932,371). View filing ↗
- Section 06, 2021 vote. Form 8-K, filed 2021-06-25. Item 5.07 · say-on-pay result. As reported: 80.24% (votes for as printed: 43,546,830). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-06-12. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 536,966 + equity 0 + all other 0 = 536,966, summed across the director compensation table rows.
- Scholar Rock Holding Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Scholar Rock Holding Corporation's own proxy. As printed: 33,300,927. View filing ↗
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Mirati Therapeutics, Section 10b CEO total. DEF 14A, filed 2023-04-06. CEO total compensation as printed in Mirati Therapeutics's own proxy. As printed: 11,937,371. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Amicus Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. View filing ↗
- Syndax Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. View filing ↗
- Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
- Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
- Deciphera Pharmaceuticals (subject), Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in Deciphera Pharmaceuticals's own proxy. As printed: 6,010,712. View filing ↗
- NGM Biopharmaceuticals, Section 10b CEO total. DEF 14A, filed 2023-03-29. CEO total compensation as printed in NGM Biopharmaceuticals's own proxy. As printed: 5,933,500. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Agios Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. View filing ↗
- Y-mAbs Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. View filing ↗
- Coherus BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Seres Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Seres Therapeutics's own proxy. As printed: 1,775,549. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Section 10a, Syndax Pharmaceuticals reciprocity. DEF 14A. Syndax Pharmaceuticals names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Y-mAbs Therapeutics reciprocity. DEF 14A. Y-mAbs Therapeutics names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Coherus BioSciences reciprocity. DEF 14A. Coherus BioSciences names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, SpringWorks Therapeutics reciprocity. DEF 14A. SpringWorks Therapeutics names Deciphera Pharmaceuticals in its own disclosed peer group (read from its most recent proxy). View filing ↗